In conclusion, the evidence from epi demiological studies, migration studies, animal studies, randomized trials and outcome studies all show that reducing salt intake in the population has substantial health benefits. 8 The paper by O'Donnell et al. should not divert us from working towards reducing salt intake. Most devel oped countries have adopted policies to reduce salt intake by persuading the food industry to reformulate food with less salt, as is occurring successfully in the UK, 9, 10 and are encouraging consumers to change their attitude and behavior towards salt in their diet. The World Health Organization has recommended salt reduction as one of the top three priorities to tackle the global noncommunicable disease crisis. A reduction in population salt intake from the current level of 9-12 g per day to the recom mended level of less than 5-6 g per day will have major beneficial effects on health along with major cost savings around the world. Indeed, reducing salt intake is one of the most costeffective public health policies. Comparisons of spot v 24 h urine samples for population estimates of salt intake [abstract] . J. Hum. Hypertens. 25, 628 (2011) . 3. Paterna, S., Gaspare, P., Fasullo, S., Sarullo, F. M. & Di Pasquale, P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin. Sci. (Lond.) 114, 221-230 (2008 
GLOMERULAR DISEASE
Perspectives on maintenance therapy in lupus nephritis
James E. Balow
Maintenance immunosuppressive drug therapy is necessary to counter the propensity of lupus nephritis to relapse. Claims that mycophenolate mofetil might be the magic bullet for both induction and maintenance therapies merit critical reappraisal due to inconsistent evidence of the superiority of mycophenolate mofetil over azathioprine, as well as its inordinately greater cost. 5 These investigators ran domized patients in various stages of remis sion to maintenance therapy with quarterly pulse cyclophosphamide, azathio prine or mycophenolate mofetil. Provocative results suggested that both azathioprine and myco phenolate mofetil were more effective than quarterly pulse cyclophosphamide in pre venting relapse, progressive renal failure and death. Critics of these results were concerned that the rates of adverse out comes were substantially higher than those observed in previous studies and suggested the possibility that demographic factors may have led to the unanticipated results.
The recent international trial reported by Dooley et al. directly compared azathioprine and mycophenolate mofetil as maintenance therapies for lupus nephritis. 6 The investi gators randomly assigned 227 patients to one of these agents after the induction of initial remission. Treatment failure rates were approximately twofold higher in the ''
...achieving a complete cure ... is exceptional, occurring in less than 5% of patients ''
group treated with azathioprine than in the group receiving mycophenolate mofetil maintenance therapy (P = 0.003).
Contrary to these results are the findings from the multicenter European MAINTAIN Nephritis Trial, which cast doubt on the position that mycophenolate mofetil pro vides superior efficacy over azathioprine as maintenance therapy in lupus nephri tis. 7 The MAINTAIN Trial results showed no significant differences in either rates of renal flares or in the evolution of renal biopsy changes (based on changes in activ ity or chronicity scores) in the group treated with mycophenolate mofetil compared with the group treated with azathioprine.
Comparative studies on the relative immunosuppressive capacities of myco phenolate mofetil and azathioprine for posttransplantation maintenance regi mens and for the treatment of other glo merular diseases are informative, although immuno logic mechanisms are distinct from those involved in the pathogenesis of lupus nephritis. Indeed, FDA approval of myco phenolate mofetil for antirejection therapy was based on the fact that acute rejection rates were lower than those observed with adjunctive azathioprine therapy. The fact that the halflife of renal allografts was not commensurately improved by mycopheno late mofetil therapy is provocative. Further challenges to the claims that mycopheno late mofetil is advantageous over azathio prine were presented by Remuzzi et al., who reported results from a controlled trial comparing azathioprine and myco phenolate mofetil as adjuncts to steroids and calci neurin inhibitors in renal allograft recipients.
8 These investigators found no significant differences in allograft function between groups and, in light of the more than tenfold greater costs of mycopheno late mofetil over azathioprine maintenance therapy, they suggested that there was weak if any justification for the common transplant practice favoring mycopheno late mofetil over azathioprine as adjunc tive antirejection therapy. Finally, a recent analysis of transplant registry data also indi cates that the rates of renal allograft failure from recurrent glomerular disease are the same whether mycophenolate mofetil or azathioprine is used as anti rejection maintenance therapy.
9
Because humoral immune mechanisms are known to be involved in both lupus nephritis and in several forms of renal vas culitis, results of studies of maintenance immunosuppression in antineutrophil cytoplasmic antibody (ANCA)associated vasculitis may offer relevant information. In this regard, a recent study by Hiemstra et al. in patients with ANCAassociated renal vasculitis showed that azathioprine is not just equivalent to, but is actually superior to, mycophenolate mofetil maintenance therapy as measured by relapsefree renal survival.
10
Should the above findings showing over lapping effects of mycophenolate mofetil and azathioprine be surprising? Not when one considers the fact that they both func tion as purine antimetabolites, though by different pharmacologic mechanisms. The active metabolite of mycophenolate mofetil, mycophenolic acid, preferentially binds to inosine monophosphate dehydrogenase, an enzyme that converts inosine to guano sine and is necessary for normal DNA synthesis. In the case of azathioprine, its active metabolite, 6mercaptopurine, leads to the inter calation of a fraudulent thio guanine nucleotide that in turn impairs subsequent DNA replication. Impairment of purine metabolism by either mecha nism has major effects on the prolifera tion of activated T lymphocytes, and to a lesser extent, B lymphocytes, although neither mechanism seems to have direct effects on autoantibodyproducing mature plasma cells.
Mycophenolic acid was discovered in 1913 as a natural product of certain fungi. It was studied first for its antibacterial effects and later in the mid1900s for its potential immunosuppressant properties, including in some pilot clinical studies in arthritis and psoriasis. Interestingly, zeal for developing this compound waned for a few decades until a new conjugate, myco phenolate mofetil, was synthesized and studied in preclinical models of auto immunity in the 1970s. It was brought to market in the 1990s following FDA approval based on evidence of its superiority over azathio prine in reducing the risk of acute allograft rejection episodes. Interest soon followed for its application to multiple autoimmune dis orders and particularly as a less toxic alternative to cyclophosphamide therapy. Indeed, some enthusiasts entertained the prospect that myco phenolate mofetil would likely show superior efficacy to both cyclophosphamide and azathioprine, a perspective that has not been realized, despite a plethora of editorial commen taries to this effect. Placed in historical context, mycophenolate mofetil seems to fall in line with the typical lifecycle of new scientific discoveries showing changes in a hypothetical 'enthusiasm index' over time (Figure 1 ). According to this scheme, new treatment options are typically embraced by a burst of enthusiasm based on subjec tive impressions of efficacy. This phase is typically followed by a period of doubt, based on results of objective, controlled studies; demonstrating the true position of the agent in the thera peutic armentarium often requires careful balancing of the evi dence for efficacy, toxi city and cost of the product. Such is the case with mycopheno late mofetil, where its less than originally conceived efficacy, its more than originally conceived toxicity (not discussed here), and certainly its inordinately burdensome costs leave its ultimate ranking among the choices of immuno suppressive agents in substantial doubt. 
TRANSPLANTATION
The global role of kidney transplantation
Guillermo Garcia Garcia, Paul Harden and Jeremy R. Chapman on behalf of the Joint International Society of Nephrology and International Federation of Kidney Foundations World Kidney Day Steering Committee 2012
World Kidney Day on March 8, 2012 provides a chance to reflect on the success of kidney transplantation as a therapy for end-stage renal disease that surpasses dialysis treatments in terms of cost-effectiveness and improving quality and length of life.
Garcia Garcia, G. et al. Nat. Rev. Nephrol. 8, 138-140 (2012); published online 7 February 2012; doi:10.1038 /nrneph.2012 Kidney transplantation-an experimental, risky and very limited treatment option 50 years ago-is now routine clinical prac tice in more than 80 countries. What was once limited to a few individuals in a small number of academic centers is routinely transforming lives in most highincome and mediumincome countries. The largest numbers of kidney transplantations are performed in the USA, China, Brazil and India, whereas the greatest population adjusted access to kidney transplantation occurs in Croatia, Portugal, Spain, Austria, the USA and Norway. 1 Almost all countries, however, have rising waiting lists and donor organ availability meets only 10% of global needs. Barriers to the broader application of kidney transplantation include economic limitations, but the major restrictions on kidney transplantation rates are the short age of donated organs and the number of trained medical workforces with the required expertise.
The first successful kidney transplanta tion was carried out between identical twins in 1954.
2 Between 1965 and 1980 patient survival after kidney transplanta tion progressively increased towards 90% and graft survival rose to at least 60%. 30 years on, unsensitized recipients of first deceased or living donor kidney transplants can expect 1year patient survival rates of 95% and transplant survival of at least 90%.
2 Recent developments have also led to excellent results in ABOincompatible recipients with lowtiter ABO antibodies, and desensitization protocols and paired kidney exchange programs now afford real opportunities for individuals who have high titers of donorspecific antiHLA anti bodies and were previously deemed unsuitable for transplantation. Kidney transplantation improves life expectancy and quality of life compared with maintenance dialysis. In the USA between 1991 and 1997, mor tality after 3-4 years was 68% lower for kidney transplant recipients than for those remaining on the transplant waiting list, with 20-39yearold transplant recipients predicted to live 17 years longer than those remaining on the transplant waiting list.
3
Despite a resourcepoor environment, 1year and 5year survival rates of 92% and 85%, respectively, have been achieved after kidney transplantation in Pakistan. 4 Worldwide, however, ethnic minorities, disadvantaged populations and African Americans generally suffer worse out comes than white patients. Although excel lent longterm results can be achieved in resourcepoor environments, most patients and their families are not able to afford the high cost of immunosuppressants and anti viral medications that reduce the risk of graft loss and mortality.
5
The number of potential candidates for renal replacement therapy is growing rapidly but longterm dialysis is prohibitive in most emerging economies. The major ity of patients commencing dialysis in low income countries die or stop treatment within 3 months of dialysis initiation due to cost restraints. 6 Transplantation, espe cially when it preempts dialysis, provides a mechanism both to expand access and reduce costs for the successful treatment of endstage renal disease (ESRD).
Substantial disparities exist in access to transplantation worldwide (Figure 1 ).
1 The relationship between the rate of transplanta tion and the Human Development Index (HDI) of individual nations illustrates not only the reduced rate of transplantation in countries with low and middle HDI levels but also the large spread of transplantation rates even among the wealthier nations. Kidney transplantation rates >30 per million population in 2010 were generally restricted to Western Europe, the USA, and Australia, with a slightly broader spread of countries achieving 20-30 transplantations per million population. In addition to this variability, substantial withincountry dis parities also exist in transplantation rates among women and ethnic minorities. Even in the USA, which has high overall transplantation rates, African Americans, women and the poor fare badly compared with white individuals, men and more affluent populations.
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Developing countries have poor trans plantation rates because of a combination of factors: low infrastructure levels; insuffi cient training; lack of legal frameworks to govern brain death; religious, cultural and social constraints; patient apprehension;
